In A Role Reversal, Takeda Sends Alzheimer's Compound To Tokyo University
This article was originally published in PharmAsia News
Executive Summary
Takeda discontinued development of TAK-070, but instead of discarding it, out-licensed it to its academic research partner.
You may also be interested in...
Alzheimer’s Research To Be More Collaborative, Better Funded Under National Plan
Most of the additional money will help support two trials – one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer’s plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.